{
  "id": 12282552,
  "title": "Up 57% since June: this AI-picked pharma stock keeps climbing",
  "url": "https://urgent.news/2026/10/06/up-57-since-june-this-ai-picked-pharma-stock-keeps-climbing",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T02:16:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/up-57-since-june-this-aipicked-pharma-stock-keeps-climbing-4933262"
  },
  "original_language": "en",
  "account": "In the span of four months, the AI-picked pharmaceutical stock Amneal Pharmaceuticals (NASDAQGS:AMRX) has surged by 57.75%, according to Investing.com. The stock was initially selected by the company's AI models back on June 1, 2026, and members who acted on the signal have been rewarded with a significant gain. Since the pick date, the stock has seen a 57.75% increase, despite weathering an initial post-earnings dip. This performance has been bolstered by two key catalysts: the FDA approval of lanreotide injection and Amneal's Q2 2026 earnings report. The Q2 earnings report delivered an adjusted EPS of $0.30, surpassing the consensus of $0.23 by 30.4%, against revenue of $796.2 million. The FDA approval of lanreotide injection added further credibility to the stock's performance. As of this month's review, the stock trades at 96.2% of its 52-week high, indicating a position of sustained strength. Over the past year and a half since the AI model's launch, the Mid-Cap Movers strategy, which includes Amneal Pharmaceuticals, has outperformed the S&P Midcap 400 by 48.5 percentage points.",
  "summary": null,
  "key_points": [
    "Amneal Pharmaceuticals stock up 57.75% in four months",
    "FDA approved lanreotide injection, Q2 earnings exceeded expectations",
    "Mid-Cap Movers strategy outperformed S&P Midcap 400 by 48.5%"
  ],
  "editors_take": "This surge in Amneal Pharmaceuticals' stock cements the credibility of the AI model's selection process and boosts confidence in the Mid-Cap Movers strategy that includes it.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}